- Conditions
- Retinal Detachment With Multiple Breaks, Unspecified Eye, Proliferative Vitreoretinopathy
- Interventions
- Intravitreal aflibercept injection, Sham control
- Drug · Other
- Lead sponsor
- M. Ali Khan, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 577–600
of 839
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Macular Degeneration, Age-Related, Geographic Atrophy
- Interventions
- Galegenimab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 48
- States / cities
- Bakersfield, California • Encino, California • Fullerton, California + 43 more
- Conditions
- Retinal Disease
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 10 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Non-proliferative Diabetic Retinopathy
- Interventions
- KSI-301, Sham injection
- Drug · Other
- Lead sponsor
- Kodiak Sciences Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 253 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Fullerton, California + 42 more
- Conditions
- Diabetic Retinopathy, Posterior Vitreous Detachment, Disease Progression
- Interventions
- ocriplasmin 0.0625mg, ocriplasmin 0.125mg, Sham injection
- Drug
- Lead sponsor
- ThromboGenics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Campbell, California • Irvine, California + 6 more
- Conditions
- X-Linked Retinitis Pigmentosa
- Interventions
- rAAV2tYF-GRK1-RPGR
- Biological
- Lead sponsor
- Beacon Therapeutics
- Industry
- Eligibility
- 8 Years to 50 Years · Male only
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 6
- States / cities
- Jacksonville, Florida • Boston, Massachusetts • Cincinnati, Ohio + 3 more
- Conditions
- Vitreous Detachment, Diabetic Retinopathy
- Interventions
- Vitrase
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 4
- States / cities
- Beverly Hills, California • New York, New York • McAllen, Texas + 1 more
- Conditions
- Central Retinal Artery Occlusion
- Interventions
- KUS121 high dose, KUS121 low dose, Sham procedure
- Drug
- Lead sponsor
- Kyoto Drug Discovery and Development Co., Ltd.
- Industry
- Eligibility
- 20 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 11
- States / cities
- Encino, California • Huntington Beach, California • Oakland, California + 8 more
- Conditions
- Geographic Atrophy
- Interventions
- OpRegen
- Biological
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 15
- States / cities
- Beverly Hills, California • Sacramento, California • San Francisco, California + 12 more
- Conditions
- Cytomegalovirus Retinitis, HIV Infections
- Interventions
- Zidovudine, Sargramostim, Ganciclovir
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years to 65 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1992
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Boston, Massachusetts • New York, New York + 1 more
- Conditions
- Macular Degeneration
- Interventions
- Omega-3 fatty acid
- Dietary Supplement
- Lead sponsor
- Wills Eye
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 4
- States / cities
- Cherry Hill, New Jersey • Bethlehem, Pennsylvania • Huntingdon Valley, Pennsylvania + 1 more
- Conditions
- Combretastatin A4 Phosphate, Age-related Macular Degeneration, AMD, CNV, Choroidal Neovascularization
- Interventions
- Combretastatin A-4 Phosphate
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Macular Degeneration
- Interventions
- RO6867461
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 5
- States / cities
- Colorado Springs, Colorado • Baltimore, Maryland • Dallas, Texas + 2 more
- Conditions
- Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind, Retinal Disease, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Vision Disorders
- Interventions
- Ultevursen, Sham-procedure
- Drug · Other
- Lead sponsor
- Laboratoires Thea
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 10
- States / cities
- San Diego, California • San Francisco, California • Miami, Florida + 7 more
- Conditions
- Usher Syndrome, Retinitis Pigmentosa
- Interventions
- SAR421869
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Retinopathy of Prematurity
- Interventions
- Ranibizumab, Laser therapy
- Drug · Procedure
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- Not listed
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 12
- States / cities
- Loma Linda, California • Sacramento, California • Aurora, Colorado + 9 more
- Conditions
- Wet Age Related Macular Degeneration, Wet AMD
- Interventions
- NT-101 Low Dose, NT-101 High Dose
- Drug
- Lead sponsor
- NexThera Co., Ltd.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 4
- States / cities
- Rosedale, Maryland • Durham, North Carolina • Erie, Pennsylvania + 1 more
- Conditions
- Age Related Macular Degeneration
- Interventions
- NeoVista Ophthalmic System
- Device
- Lead sponsor
- NeoVista
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Honolulu, Hawaii
- Conditions
- Age-Related Macular Degeneration
- Interventions
- E10030, ranibizumab, E10030 sham intravitreal injection
- Drug
- Lead sponsor
- Ophthotech Corporation
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 627 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 49
- States / cities
- Tucson, Arizona • Fresno, California • La Jolla, California + 43 more
- Conditions
- Intraocular Inflammation, Suspected Endophthalmitis
- Interventions
- Non Applicable
- Other
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 155,413 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Tarrytown, New York
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- AKST4290, Placebo, Aflibercept
- Drug
- Lead sponsor
- Alkahest, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 3
- States / cities
- Beverly Hills, California • St. Petersburg, Florida • Reno, Nevada
- Conditions
- Retinal Pigment Epithelial Detachment
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- Clement K. Chan
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Palm Desert, California • Rapid City, South Dakota
- Conditions
- Age-Related Macular Degeneration
- Interventions
- AG-013,958
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 30
- States / cities
- Mesa, Arizona • Oro Valley, Arizona • Phoenix, Arizona + 27 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Ranibizumab, Aflibercept
- Drug
- Lead sponsor
- Associated Retinal Consultants, Michigan
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Royal Oak, Michigan